Bicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 Congress
Bicycle Therapeutics (NASDAQ: BCYC) will present data on its Bicycle Radionuclide Conjugates (BRC®) at the European Association of Nuclear Medicine (EANM) 2024 Congress in Hamburg, Germany, from October 19-23. The German Cancer Consortium (DKTK) will reveal the first human imaging data for a BRC targeting MT1-MMP, a tumor antigen common in many cancers, on October 22. Additionally, Bicycle Therapeutics will share an e-poster on BRCs for radioisotope delivery to solid tumors. A conference call and webcast will be held on October 23 at 8 a.m. ET to discuss the data and the company's radiopharmaceutical strategy. The call can be accessed by dialing +1-833-816-1408 (U.S.) or +1-412-317-0501 (international) and requesting the Bicycle Therapeutics call. A live webcast and replay will be available on the company's website.
Bicycle Therapeutics (NASDAQ: BCYC) presenterà dati sui suoi Bicycle Radionuclide Conjugates (BRC®) durante il Congresso della European Association of Nuclear Medicine (EANM) 2024 che si svolgerà a Amburgo, Germania, dal 19 al 23 ottobre. Il Consorzio Tedesco per il Cancro (DKTK) rivelerà i primi dati di imaging umano per un BRC che mira a MT1-MMP, un antigene tumorale comune in molti tipi di cancro, il 22 ottobre. Inoltre, Bicycle Therapeutics condividerà un e-poster sui BRC per la somministrazione di radioisotopi ai tumori solidi. Una call e webcast si terrà il 23 ottobre alle 8 a.m. ET per discutere i dati e la strategia radiofarmaceutica dell'azienda. La chiamata può essere raggiunta componendo +1-833-816-1408 (U.S.) o +1-412-317-0501 (internazionale) e richiedendo la chiamata di Bicycle Therapeutics. Un webcast dal vivo e una registrazione saranno disponibili sul sito web dell'azienda.
Bicycle Therapeutics (NASDAQ: BCYC) presentará datos sobre sus Bicycle Radionuclide Conjugates (BRC®) en el Congreso de la Asociación Europea de Medicina Nuclear (EANM) 2024 que se llevará a cabo en Hamburgo, Alemania, del 19 al 23 de octubre. El Consorcio Alemán contra el Cáncer (DKTK) revelará los primeros datos de imagen humanos para un BRC que apunta a MT1-MMP, un antígeno tumoral común en muchos tipos de cáncer, el 22 de octubre. Además, Bicycle Therapeutics compartirá un e-poster sobre BRCs para la entrega de radioisótopos a tumores sólidos. Una llamada de conferencia y webcast se llevará a cabo el 23 de octubre a las 8 a.m. ET para discutir los datos y la estrategia radiofarmacéutica de la empresa. La llamada se puede acceder marcando +1-833-816-1408 (EE.UU.) o +1-412-317-0501 (internacional) y solicitando la llamada de Bicycle Therapeutics. Un webcast en vivo y la repetición estarán disponibles en el sitio web de la empresa.
바이시클 테라퓨틱스 (NASDAQ: BCYC)는 10월 19일부터 23일까지 독일 함부르크에서 열리는 유럽 핵의학 협회(EANM) 2024 콘그레스에서 자사의 바이시클 방사성 동위원소 접합체(BRC®)에 대한 데이터를 발표할 예정입니다. 독일 암 컨소시엄(DKTK)는 10월 22일 다수의 암에서 공통적으로 발견되는 종양 항원 MT1-MMP를 대상으로 한 BRC의 첫 번째 인간 이미징 데이터를 공개할 것입니다. 또한 바이시클 테라퓨틱스는 고형 종양으로의 방사성 동위원소 전달을 위한 BRC에 대한 e-포스터를 공유할 예정입니다. 데이터 및 회사의 방사성 의약품 전략에 대해 논의하기 위해 10월 23일 오전 8시(ET)에 컨퍼런스 콜 및 웹캐스트가 진행됩니다. 콜은 +1-833-816-1408 (미국) 또는 +1-412-317-0501 (국제)로 전화하여 바이시클 테라퓨틱스 콜을 요청하면 접속할 수 있습니다. 웹사이트에서 실시간 웹캐스트 및 재생이 제공됩니다.
Bicycle Therapeutics (NASDAQ: BCYC) présentera des données sur ses Bicycle Radionuclide Conjugates (BRC®) lors du Congrès de l'Association Européenne de Médecine Nucléaire (EANM) 2024 à Hambourg, en Allemagne, du 19 au 23 octobre. Le Consortium Allemand contre le Cancer (DKTK) dévoilera le 22 octobre les premières données d'imagerie humaine pour un BRC ciblant le MT1-MMP, un antigène tumoral commun à de nombreux cancers. En outre, Bicycle Therapeutics partagera un e-poster sur les BRC pour la livraison de radio-isotopes vers des tumeurs solides. Un appel conférence et webcast aura lieu le 23 octobre à 8 h, heure de l'Est, pour discuter des données et de la stratégie radiopharmaceutique de l'entreprise. L'appel peut être accessible en composant le +1-833-816-1408 (États-Unis) ou le +1-412-317-0501 (international) et en demandant l'appel de Bicycle Therapeutics. Un webcast en direct et un replay seront disponibles sur le site web de l'entreprise.
Bicycle Therapeutics (NASDAQ: BCYC) wird Daten zu seinen Bicycle Radionuclide Conjugates (BRC®) beim Kongress der Europäischen Gesellschaft für Nuklearmedizin (EANM) 2024 in Hamburg, Deutschland, vom 19. bis 23. Oktober vorstellen. Das Deutsche Konsortium für Krebsforschung (DKTK) wird am 22. Oktober die ersten menschlichen Bildgebungsdaten zu einem BRC präsentieren, das auf MT1-MMP abzielt, ein Tumorantigen, das in vielen Krebsarten verbreitet ist. Darüber hinaus wird Bicycle Therapeutics ein E-Poster zu BRCs für die Lieferung von Radioisotopen an solide Tumoren teilen. Am 23. Oktober um 8 Uhr ET wird ein Konferenzanruf und Webcast abgehalten, um die Daten und die radiopharmazeutische Strategie des Unternehmens zu besprechen. Der Anruf kann unter +1-833-816-1408 (USA) oder +1-412-317-0501 (international) erreicht werden, indem man um den Anruf von Bicycle Therapeutics bittet. Ein Live-Webcast und eine Aufzeichnung sind auf der Unternehmenswebsite verfügbar.
- None.
- None.
Company to host conference call and webcast on Wednesday, Oct. 23, at 8 a.m. ET to review the data and outline radiopharmaceuticals strategy
The German Cancer Consortium (DKTK), part of a cooperative network with the German Cancer Research Center (DKFZ), will present the first human imaging data for a BRC targeting MT1-MMP, a tumor antigen overexpressed in many cancers, during an oral presentation. In an online-only poster (e-poster), the company will present information about BRCs for radioisotope delivery to solid tumors. Additionally, Bicycle Therapeutics will host a conference call and webcast for analysts and investors on Wednesday, Oct. 23, at 8 a.m. ET to review the data and outline the company’s radiopharmaceuticals strategy.
Oral Presentation by DKTK:
Title: Preclinical characterization of a phage display derived MT1-MMP-specific bicyclic peptide for radiotheranostic applications
Session Number: 1504
Session Title: M2M Track - TROP Session: Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: Targeted Radionuclide Therapy
Date and Time: Tuesday, Oct. 22, at 3:50-4 p.m. CEST
Presentation Number: OP-673
Presenter: Ann-Christin Eder, Ph.D., University Medical Center Freiburg
E-Poster by Bicycle Therapeutics:
Title: Bicycle Radionuclide Conjugates for radioisotope delivery to solid tumors
Session Number: EP-03
Session Title: Preclinical Studies -> A1 Medical Preclinical -> A13 Preclinical Oncology
e-Poster Number: EP-0032
Lead Author: Gemma Mudd, Ph.D., Bicycle Therapeutics
Conference Call and Webcast Information
Bicycle Therapeutics will host a conference call and webcast on Wednesday, Oct. 23, at 8 a.m. ET to review the first human imaging data and outline the company’s radiopharmaceuticals strategy. To access the call, please dial +1-833-816-1408 (
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle Radionuclide Conjugates (BRC®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.
Bicycle Therapeutics is headquartered in
Forward Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential to develop differentiated radiopharmaceutical molecules using Bicycle’s platform, and Bicycle’s anticipated progress across its R&D pipeline and the advancement of its product candidates. Bicycle may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in research and development and in the initiation, progress and completion of clinical trials and clinical development of Bicycle’s product candidates; the risk that Bicycle may not realize the intended benefits of its technology or partnerships; timing of results from clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; the risk that trials may have unsatisfactory outcomes; potential adverse effects arising from the testing or use of Bicycle’s product candidates; and other important factors, any of which could cause Bicycle’s actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled “Risk Factors” in Bicycle’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 6, 2024, as well as in other filings Bicycle may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Bicycle expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241016119406/en/
Investors:
Stephanie Yao
SVP, Investor Relations and Corporate Communications
stephanie.yao@bicycletx.com
857-523-8544
Matthew DeYoung
Argot Partners
ir@bicycletx.com
212-600-1902
Media:
Jim O’Connell
Weber Shandwick
media@bicycletx.com
312-988-2343
Source: Bicycle Therapeutics plc
FAQ
When will Bicycle Therapeutics present data at the EANM 2024 Congress?
What is the focus of Bicycle Therapeutics' presentation at the EANM 2024 Congress?
When is the conference call and webcast by Bicycle Therapeutics?
How can I join the Bicycle Therapeutics conference call?
Where can I find the live webcast and replay of the Bicycle Therapeutics conference call?
